Clinical Oncology - 2016;3(02)

Clinical Oncology

MAY 20, 2016

Clinical Oncology

MAY 20, 2016

[Non-surgical treatment of the biliary tract and gallbladder cancer]

PIKÓ Béla, LACZÓ Ibolya

[Biliary tract cancers are rare, hence only a few high level of evidences related to their treatment are available. The successful treatment and the only chance for long-term survival are based on the radical surgical resection. After the fl uoropyrimidin based protocols chemotherapy regimens prefer gemcitabine combinations (cisplatin, oxaliplatin, capecitabine) or FOLFIRINOX, considering the patient performance status as well. There are no registered targeted therapy in this indication, the... tovább »

Clinical Oncology

MAY 20, 2016

[Treatment of childhood tumors of mesenchymal origin]

CSÓKA Monika

[Mesenchymal cells can be differentiated into skeletal muscle, smooth muscle, adipose tissue, fi brous tissue, bone and cartilage. Tumors can be originated from these tissues as benign tumors - fibroma, lipoma, osteoma, chondroma, haemangioma, myoma, etc. or as malignant tumors - in childhood, most commonly rhabdomyosarcomas, osteosarcoma, Ewing sarcoma, less often fi brosarcoma, liposarcoma or other rare types. Clinically, the outcome of these tumors have improved signifi cantly in the last... tovább »

Clinical Oncology

MAY 20, 2016

[Mediastinal tumours and their therapy]

AGÓCS László

[Due to the tissue structure of the mediastinum a large variety of tumours and multiple systemic malignant disease may occur in the region. The tumours show a variation depending upon age and localization besides their signifi cant alterations. Based on the most accepted Shield classifi cation, the author discusses the types, characters and therapeutic discipline of the tumours in the mediastinal region. The author focuses on the surgical indications, their options and forms, highlighting on... tovább »

Clinical Oncology

MAY 20, 2016

[Systemic treatment of gastrooesophageal adenocarcinoma]

PFEIFFER Per, MOEHLER H. Markus

[Few of chemotherapeutic drugs are effective and used for the treatment aGEA. Palliative chemotherapy prolongs overall survival and improves quality of life. The median OS in large randomized trials are approaching 12 months but in unselected populations the median OS only around 6 months. The median age for mEGA is around 70 years but the median age in most of the randomized trials is only around 60 years or even younger and therefore patients in trials are highly selected. A number of... tovább »

Clinical Oncology

MAY 20, 2016

[Tumormetabolism]

SEBESTYÉN Anna, HUJBER Zoltán, JENEY András, KOPPER László

[The interrelations between the well-known characterized oncogenic effects (genetic and epigenetic), the related metabolic alterations and the metabolic reprogramming have high interest in recent studies of tumorgenesis, tumor progression and therapeutic response. Certain tumor cells could possess various metabolic profi les (even independently from their histological type) based on their metabolic changes. These can be characterized by different nutrient demand and utilization pathways... tovább »

Clinical Oncology

MAY 20, 2016

[Complications of infusion treatment with emphasis on extravasation of cytostatics]

HARISI Revekka

[The extravasation of cytostatics is the most signifi cant complication of infusion therapy in cancer treatment. Extravasation refers to the inadvertent infi ltration of cytostatic drugs into subcutaneous or subdermal tissues surrounding the intravenous or intraarterial administration site. According to literature data incidence estimates between 0,01-7%. Extravasated drugs are classifi ed according to their potential for causing damage as vesicant, irritant and nonvesicant. Knowledge of risk... tovább »

Clinical Oncology

MAY 20, 2016

[The role of hospice in the management of cancer patients]

TORGYIK Pál

[There is the relationship between the oncological treatment and hospice care proved by the data on morbidity and mortality. Cancer treatment is just partially effective since besides the growing incidence of new patients (90 091 in 2013) in Hungary, the mortality rate is still high (33 278 people in 2013). Revealing the diagnosis of tumorous disease causes an incredible shock for the patients, therefore oncopsychologists have to join to the oncological treatment at a very early stage. They... tovább »